2025-04-17 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Summary Statistics:**

JNJ, Johnson & Johnson, is a multinational healthcare company.  This report analyzes JNJ's performance against the S&P 500 (VOO) based on provided data.  Key findings show JNJ underperforming VOO, exhibiting relatively low RSI and PPO indicators, and mixed recent earnings.


**1. Performance Comparison with S&P 500 (VOO):**

* **JNJ Cumulative Return:** 39.31%
* **VOO Cumulative Return:** 76.08%
* **Return Difference:** -36.8% (JNJ underperformed VOO by 36.8 percentage points)
* **Relative Divergence:** 41.0% (This indicates JNJ's underperformance is in the 41st percentile relative to its historical maximum and minimum divergence from VOO.)

The provided Alpha and Beta analysis shows mixed performance relative to the market (VOO).  While JNJ shows periods of positive alpha (outperformance), particularly in 2017-2019 and 2019-2021, more recent periods (2021-2025) show negative or low alpha, indicating underperformance relative to the market during these timeframes.  Beta is consistently around 0.1-0.7 indicating relatively low sensitivity to market movements.


**2. Recent Price Movements:**

* **Closing Price:** $153.91
* **5-Day Moving Average:** $152.46
* **20-Day Moving Average:** $157.05
* **60-Day Moving Average:** $157.70

The closing price is below both the 20-day and 60-day moving averages, suggesting a downward trend. The 5-day moving average is even lower, indicating recent price depreciation. The slight increase from the previous close ($0.19) may be a minor temporary upward movement.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.41 (Medium Risk)
* **RSI:** 38.93 (Below 40, suggesting oversold conditions)
* **PPO:** -0.23 (Negative value, indicating bearish momentum)
* **20-Day Relative Divergence Change:** +3.9 (Short-term upward movement)
* **Expected Return (2+ years):** -37.5% (JNJ is expected to underperform VOO by 37.5% over the long term based on the provided data)

The combination of low RSI, negative PPO, and negative expected return suggests a potentially bearish outlook.  The short-term upward movement (+3.9) may be a temporary fluctuation.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2024-10-23 | $1.12  | $22.47B        |
| 2024-07-25 | $1.95  | $22.45B        |
| 2024-05-01 | $1.35  | $21.38B        |
| 2024-02-16 | $1.68  | $21.39B        |
| 2023-10-27 | $10.32 | $21.35B        |

EPS shows significant volatility across the quarters, with a very high value of $10.32 in Q4 2023.  Revenue remains relatively stable around $21-22 billion.  Further investigation is needed to understand the reasons for the EPS fluctuations.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31  | $22.52B     | 68.35%        |
| 2024-09-30  | $22.47B     | 69.01%        |
| 2024-06-30  | $22.45B     | 69.40%        |
| 2024-03-31  | $21.38B     | 69.55%        |
| 2023-12-31  | $21.39B     | 68.23%        |

Revenue is relatively stable, with high and consistent profit margins.

**Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-12-31  | $71.49B     | 4.80%         |
| 2024-09-30  | $70.16B     | 3.84%         |
| 2024-06-30  | $71.54B     | 6.55%         |
| 2024-03-31  | $70.02B     | 4.65%         |
| 2023-12-31  | $68.77B     | 5.89%         |

Equity shows some fluctuation; ROE is relatively stable but shows variation.


**6. Overall Conclusion:**

Based on the provided data, JNJ currently exhibits signs of underperformance relative to the S&P 500.  Technical indicators suggest a bearish outlook, although the recent small price increase might indicate a temporary reprieve.  Earnings show significant volatility in EPS.  While the company displays strong profitability,  the long-term expected return shows significant underperformance against VOO.  Further investigation is needed into the reasons behind the EPS volatility and to determine the sustainability of the relatively high profit margins.  The provided data alone is insufficient to make a definitive investment recommendation, and additional analysis would be beneficial.
